Menopause and Weight: What Hormone Therapy Can and Cannot Do

By the Healthy Weight Loss 4 U Clinical Content Team · Published October 8, 2026 · Updated October 8, 2026 · 10 min read

Key takeaways

• SWAN (1,246 women analyzed) found fat mass gain rose from about 1.0% to 1.7% per year during the transition, while lean mass shifted from slight gain to slight loss.
• Body weight and BMI did not accelerate at the transition in SWAN; the NIA reports BMI increases in midlife were more attributable to chronological aging than to menopause.
• The Menopause Society lists weight gain among primarily age-related changes for which estrogen-containing hormone therapy is not recommended.
• FDA-labeled uses of menopausal hormone therapy are moderate to severe hot flashes and night sweats, genitourinary symptoms and, for some products, osteoporosis prevention. Weight loss is not an indication.
• Labels list contraindications such as breast cancer, active or past blood clots, and liver disease. A clinician must weigh your history first.

Does menopause cause weight gain?

Menopause is associated with a shift in body composition, more fat and slightly less lean mass, rather than a sudden jump on the scale, and much of the rise in body mass index (BMI) in midlife tracks with aging itself. The National Institute on Aging, summarizing findings from the Study of Women's Health Across the Nation (SWAN), reports that increases in BMI during midlife were more attributable to chronological aging than to the menopausal transition ^[1].

Menopause is defined as the point at which a woman has not had a period for 12 consecutive months. The time leading up to it is the menopausal transition, or perimenopause, and the average age of menopause is 51 ^[2]. SWAN enrolled 3,302 women aged 42 to 52 and has followed them for more than 25 years ^[1].

What did the SWAN study find about fat and muscle?

The most detailed body-composition analysis in SWAN found that the annual rate of fat mass gain rose from 1.0% to 1.7% around the final menstrual period while lean mass turned slightly negative. Greendale and colleagues analyzed 1,246 women (356 Black, 153 Chinese, 178 Japanese and 559 White) with repeated DXA scans, anchoring the analysis to each woman's final menstrual period (FMP). Mean age was 47.1 years at baseline and 52.2 years at FMP ^[3].

Fat mass rose 1.0% per year (about 0.25 kg) before the transition and 1.7% per year (about 0.45 kg) during it, for an estimated total gain of about 6% (about 1.6 kg) over the 3.5-year transition. Lean mass rose about 0.2% per year before the transition, then fell about 0.2% per year during it, a total loss of about 0.2 kg, and was flat afterward. The transition window in this analysis ran from about 2 years before to 1.5 years after the FMP ^[3].

Body weight and BMI told a different story. They rose steadily before and during the transition with no acceleration at the transition, then weight was flat afterward. Weight gain during the transition was about 0.25 kg per year ^[3]. That gap between weight and composition is one reason the scale can understate what is changing.

These are averages for a group, not predictions for any one woman. The analysis excluded Hispanic women because their SWAN site did not use the same DXA scanner, so it cannot speak to them, and the authors report that the pattern varied across the racial and ethnic groups studied ^[3]. Individual change depends on many factors that an average cannot capture.

What is caused by estrogen decline, and what is caused by aging?

The data do not cleanly separate the two, and anyone claiming a precise split is going beyond the evidence. In SWAN, estradiol and follicle-stimulating hormone were not measured or analyzed as exposures. The authors cite them only as plausible mechanisms because their trajectories roughly match the timing of the body-composition changes ^[3].

Several findings point to a role for aging and individual factors alongside the transition. Weight and BMI did not accelerate at the transition ^[3]. A later age at the final menstrual period attenuated fat gain, by about 0.11 percentage points per year before the transition and 0.23 per year during it, for each additional year of age at FMP ^[3]. Patterns also differed by group: Japanese women showed no significant fat gain and no significant weight or BMI gain during the transition, and Chinese women showed declines in fat mass after menopause ^[3].

The same analysis could not address belly fat directly. The authors list as a limitation that they could not consider regional body composition and visceral fat ^[3]. Excess belly fat does matter clinically: the NIA lists it among vascular risk factors related to the rate of decline in thinking speed in SWAN ^[1].

What does The Menopause Society say about hormone therapy and weight?

The Menopause Society, which published its 2022 position statement under the name North American Menopause Society, does not recommend estrogen-containing hormone therapy to treat weight gain. In its statement on hormone therapy misinformation, weight gain appears in a list of primarily age-related changes, alongside hair loss and skin changes, for which such therapy is not recommended ^[4].

The Society's 2022 position statement frames hormone therapy as the most effective treatment for vasomotor symptoms (hot flashes and night sweats) and genitourinary symptoms, and notes it has been shown to prevent bone loss and fracture ^[10]. The full text of the 2022 statement was not available for review, so this article does not characterize any section of it on fat distribution beyond what is quoted here.

Other evidence is consistent with the Society's position. SWAN found that hormone therapy did not independently predict change in any of the body-composition outcomes it measured ^[3]. In the labeled adverse-reaction table for one conjugated estrogens product, weight gain was reported in 2% to 3% of women on estrogen versus 4% on placebo, which is not a signal that the drug causes weight gain. That table is a safety listing, not a test of whether the drug prevents weight gain ^[9]. The same label lists weight increase or decrease among postmarketing reports ^[9].

What is hormone therapy FDA-labeled for?

The FDA says menopausal hormone therapies treat moderate to severe hot flashes and night sweats and vulvovaginal atrophy, now called genitourinary syndrome of menopause, and that some also prevent postmenopausal osteoporosis ^[6]. Weight loss and prevention of weight gain are not labeled indications.

Labels differ by product. The conjugated estrogens tablet label reviewed for this article lists moderate to severe vasomotor symptoms, moderate to severe vulvar and vaginal atrophy, hypoestrogenism due to hypogonadism, castration or primary ovarian failure, palliative treatment of certain cancers, and prevention of postmenopausal osteoporosis, with a note that products for vaginal atrophy alone should be considered when that is the only indication ^[9].

Labeling is changing. On November 10, 2025, the FDA asked manufacturers to remove cardiovascular disease, breast cancer and probable dementia language from the boxed warning on menopausal hormone therapies, and to remove endometrial cancer language from the boxed warning except for systemic estrogen-alone products. For systemic products, the cardiovascular disease and breast cancer warnings remain in the labeling, and the FDA asked for added language about considering therapy for moderate to severe vasomotor symptoms in women under 60 or within 10 years of menopause ^[6]. On February 12, 2026, the FDA announced approved labeling changes for a first batch of six products ^[7]. Because labels are being updated product by product, the current label for a specific product is the authoritative source.

What are the risks, and who should avoid hormone therapy?

Risk depends on age, time since menopause, the type, dose and route of therapy, and personal history, so the decision must be individualized. The Menopause Society states that benefits likely outweigh risks for most healthy symptomatic women aged younger than 60 years or within 10 years of menopause onset, and that the benefit-risk ratio appears less favorable when therapy starts more than 10 years after onset or after age 60, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia ^[5][10].

The Society also notes that transdermal routes and lower doses may reduce the risk of blood clots and stroke, that short-term estrogen-progestogen use does not meaningfully raise breast cancer risk, and that compounded "bioidentical" hormone products raise safety concerns including inconsistent dosing, impurities and limited efficacy and safety data ^[10]. It does not recommend systemic hormone therapy for breast cancer survivors, with rare exceptions made through shared decision-making ^[4]. Compounded products are not FDA-approved.

• The conjugated estrogens label lists these contraindications: undiagnosed abnormal genital bleeding; breast cancer or a history of it (except in selected metastatic disease); estrogen-dependent neoplasia; active deep vein thrombosis or pulmonary embolism, or a history of either; active arterial thromboembolic disease such as stroke or heart attack, or a history of either; known anaphylactic reaction or angioedema to the product; hepatic impairment or disease; and protein C, protein S or antithrombin deficiency or other known thrombophilic disorders ^[9].
• For systemic estrogen-alone products, an endometrial cancer boxed warning remains, and women with a uterus who take estrogen without a progestogen have an increased risk of endometrial cancer ^[6][9].
• The Society does not recommend estrogen therapy for primary prevention of heart disease or dementia in women with average-age menopause ^[4].

What this means in practice

Hormone therapy is a treatment for menopausal symptoms and bone loss, not a weight-loss treatment, and any weight plan should be built separately from that decision. The same clinician visit can cover both, but they are different questions.

Because weight can look stable while fat rises and lean mass slips, measuring body composition, not just weight, gives a more informative baseline in midlife. For general activity, CDC guidance for adults is 150 minutes of moderate-intensity activity per week and at least 2 days of muscle-strengthening activity ^[8]. The studies reviewed here did not test a menopause-specific exercise or nutrition program, so this article makes no menopause-specific claim for either.

Healthy Weight Loss 4 U offers hormone replacement therapy, body composition analysis and medical weight management at both clinics. Every program begins with a clinician evaluation, and the choice among options is made by a licensed clinician.

When to talk to a clinician

Talk to a licensed clinician if hot flashes, night sweats, sleep disruption or vaginal symptoms are affecting daily life, or if you are considering hormone therapy. Bring your personal and family history of breast cancer, blood clots, stroke, heart disease and liver disease, because these determine whether systemic hormone therapy is appropriate.

Unexpected vaginal bleeding after menopause should be evaluated promptly: the label lists undiagnosed abnormal genital bleeding as a contraindication to estrogen ^[9]. Rapid unexplained weight change, new fatigue or other new symptoms also warrant evaluation rather than assuming menopause is the cause.

Frequently asked questions

Sources

1. Research explores the impact of menopause on women's health and aging. National Institute on Aging (NIH), n.d.. nia.nih.gov/news/research-explores-impact-menopause-womens-health-and-
2. Menopause (fact sheet). Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH), n.d.. nichd.nih.gov/health/topics/factsheets/menopause
3. Changes in body composition and weight during the menopause transition. JCI Insight (Greendale et al.), 2019. insight.jci.org/articles/view/124865
4. TMS statement on HT Misinformation. The Menopause Society, 2024. menopause.org/wp-content/uploads/2024/09/TMS-statement-on-HT-Misinform
5. The 2022 hormone therapy position statement of The North American Menopause Society (abstract). Menopause journal / The Menopause Society, via RRM Academy library listing, 2022. rrmacademy.org/library/the-2022-hormone-therapy-position-statement-of-
6. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. U.S. Food and Drug Administration, 2025. fda.gov/drugs/drug-alerts-and-statements/fda-requests-labeling-changes
7. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. U.S. Food and Drug Administration, 2026. fda.gov/news-events/press-announcements/fda-approves-labeling-changes-
8. Adult Activity: An Overview. Centers for Disease Control and Prevention, n.d.. cdc.gov/physical-activity-basics/guidelines/adults.html
9. PREMARIN (conjugated estrogens) tablets prescribing information. DailyMed, U.S. National Library of Medicine (Wyeth Pharmaceuticals; label revised 4/2025), 2025. dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=258e1602-a3cf-4
10. Hormone therapy position statement release (2022). The Menopause Society, 2022. menopause.org/wp-content/uploads/press-release/ht-position-statement-r

Keep reading